ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > CD109

CD109

概要

Name:DNA polymerase alpha subunit
Target Synonym:P180,N Syndrome (Mental Retardation, Malformations, Chromosome Breakage),NSX,VEODS,Polymerase (DNA Directed), Alpha,POLA1,Polymerase (DNA-Directed), Alpha (70kD),DNA Polymerase Alpha 1, Catalytic Subunit,POLA,EC:2.7.7.7,EC 2.7.7.7,DNA Polymerase Alpha Catalytic Subunit,DNA Polymerase Alpha Catalytic Subunit P180,Polymerase (DNA) Alpha 1, Catalytic Subunit,DNA Polymerase I,Polymerase (DNA Directed), Alpha 1, Catalytic Subunit
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

製品仕様別:
製品カテゴリー別:
種類別:
タグ別:
コンジュゲート:
製造番号 種類 製品説明 構造 純度 特徴
CD9-H82E4 Human Biotinylated Human CD109 / CPAMD7 Protein, His,Avitag™ (MALS & SPR verified)
CD9-H82E4-structure
CD9-H82E4-sds
ACRO Quality

生物活性データの一部

CD9-H82E4-SPR
 CD109 SPR

Biotinylated Human CD109, His,Avitag (Cat. No. CD9-H82E4) immobilized on CM5 Chip can bind Biotinylated Human TGF-Beta 1, Avitag (Cat. No. TG1-H8217) with an affinity constant of 0.248 μM as determined in a SPR assay (Biacore 8K) (QC tested).

CD9-H82E4-MALS-HPLC
CD109 MALS images

The purity of Biotinylated Human CD109, His,Avitag (Cat. No. CD9-H82E4) is more than 85% and the molecular weight of this protein is around 150-180 kDa verified by SEC-MALS.

Synonym Name

CD109,CPAMD7,r150,p180,CPAMD7

Background

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Clofarabine CAFdA; JC0707; GZ-393590; SAR-393590; 2-Cl-2-F-araA Approved Genzyme Corp Clolar, Evoltra, Ivozall, Clofarex United States Precursor Cell Lymphoblastic Leukemia-Lymphoma Genzyme Corp 2004-12-28 Lymphoma, Large B-Cell, Diffuse; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell; Waldenstrom Macroglobulinemia; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Myeloid, Acute; Lymphoproliferative Disorders; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Histiocytosis, Langerhans-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Multiple Myeloma; Hematologic Neoplasms; Neoplasms; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Leukemia, Lymphoid; Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphoma, T-Cell, Peripheral; Intestinal Neoplasms; Solid tumours; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid; Leukemia Details
Nelarabine 506U; 506-U78; GW-506U; GW-506U78; GI-262250X; NSC-686673 Approved Novartis Pharma Ag, Glaxosmithkline Plc Arranon, ArranonG, Atriance United States Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Novartis Pharma Ag 2005-10-28 Sezary Syndrome; Mycosis Fungoides; Leukemia, T-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Waldenstrom Macroglobulinemia; Lymphoma; Leukemia; Lymphoma, Follicular; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Multiple Myeloma; Myeloproliferative Disorders; Myelodysplastic Syndromes; Plasmacytoma; Lymphoma, B-Cell, Marginal Zone Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Clofarabine (Boyen) BY-101 Phase 3 Clinical Boyen Therapeutics Inc Leukemia, Myeloid, Acute Details
Sapacitabine CS-682; CYC-682 Phase 2 Clinical Daiichi Sankyo Co Ltd Leukemia; Myelodysplastic Syndromes; Breast Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, T-Cell, Cutaneous; Carcinoma, Non-Small-Cell Lung Details
Alkasar-18 NOAC; Alkasar-18; N4-octadecyl-ara-C Phase 2 Clinical University of Zurich Cerebral Hemorrhage; Neoplasms; Atrial Fibrillation Details

This web search service is supported by Google Inc.

totopphone